Company intelligence / Profile preview

Corridor

Baltimore, Maryland, United States

Ownership: Private
Development stage: Other

Overview

Corridor Pharmaceuticals was a biotechnology company focused on developing small molecule inhibitors for cardiovascular and oncology indications. The company's lead programs targeted arginase and phosphodiesterase 1 (PDE1) to treat conditions such as pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis. Corridor was acquired by AstraZeneca in 2014 to bolster its cardiovascular and metabolic disease pipeline, specifically gaining access to its PDE1 inhibitor program.

Therapeutic areas: OncologyCardiovascularPulmonology
Modalities: Small molecule
Industry: Biotech

Partnerships

AstraZeneca

Beyond the preview

Go deeper on Corridor.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Corridor.

Explore the full profile